Antifungal medication improves treatment of sarcoidosis

Antifungal medication improves treatment of sarcoidosis: A three arm, randomised controlled trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN34533986

Enrollment

Registered

2010-07-29

Start date

2003-08-15

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary sarcoidosis Haematological Disorders Sarcoidosis

Interventions

1. Corticosteroid (12 - 16 mg methylprednisolone every second day) 2. Itraconazol (200 mg daily) 3. Corticosteroid and Itraconazol in combination Patients were controlled at 2-3 months. The total dur

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subjects with sarcoidosis diagnosed using established criteria at the Department of Pulmonary and Allergic diseases at the Medical Center, University hospital of Ljubljana, Slovenia. 2. Informed consent

Exclusion criteria

Exclusion criteria: Severe sarcoidosis requiring immediate treatment

Design outcomes

Primary

Measure	Time frame
1. X-ray was taken before and after treatment. A grading scheme for the presence of granulomas was used as described previously. The x-rays were read by two experienced radiologists, unaware of the status of the patient, grading granulomas according to a numerical score (0-4), judging size and extension of the infiltrates (0 = normal, 1= ca 25% of lung field involved, 2 = up to 50%, 3 = up to 75%, and 4 = virtually the whole lung field involved). Repeat evaluations on two successive occasions showed only minor deviations in the classification. 2. Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) was measured using standard techniques 3. Inflammatory indicators of sarcoidosis were determined 3.1. The soluble IL-2 receptor (sIL-2R) in serum was quantified using an ELISA commercial kit (Milenia Biotech, Badnauheim, Gemany) and expressed as U/mL 3.2. Angiotensin converting enzyme in serum (sACE) was determined using a colorimetric method and expressed as ìKat/L 3.3. Chitotriosidase (CTO) activity in serum was determined	—

Measure

Time frame

1. X-ray was taken before and after treatment. A grading scheme for the presence of granulomas was used as described previously. The x-rays were read by two experienced radiologists, unaware of the status of the patient, grading granulomas according to a numerical score (0-4), judging size and extension of the infiltrates (0 = normal, 1= ca 25% of lung field involved, 2 = up to 50%, 3 = up to 75%, and 4 = virtually the whole lung field involved). Repeat evaluations on two successive occasions showed only minor deviations in the classification. 2. Diffusing Capacity of the Lung for Carbon Monoxide (DLCO) was measured using standard techniques 3. Inflammatory indicators of sarcoidosis were determined 3.1. The soluble IL-2 receptor (sIL-2R) in serum was quantified using an ELISA commercial kit (Milenia Biotech, Badnauheim, Gemany) and expressed as U/mL 3.2. Angiotensin converting enzyme in serum (sACE) was determined using a colorimetric method and expressed as ìKat/L 3.3. Chitotriosidase (CTO) activity in serum was determined

—

Countries

Slovenia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026